NCT02516241 · OUTCOME

Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · Source last updated 2026-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).

What was measured

Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

Analysis population: The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as: \<25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND \<25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.

Groups in this outcome

Combination Therapy

MEDI4736 (Durvalumab) + Tremelimumab

Monotherapy

MEDI4736 (Durvalumab)

Standard of Care

Standard of Care Chemotherapy Treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Combination Therapy	137
Monotherapy	137
Standard of Care	137

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Combination Therapy	29.2	Not reported	Not reported	Not reported	Not reported
Monotherapy	27.7	Not reported	Not reported	Not reported	Not reported
Standard of Care	59.1	Not reported	Not reported	Not reported	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.160
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
0.448
estimate Comment
The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY
p Value
<0.0001
p Value Comment
P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.
param Type
Odds Ratio (OR)
param Value
0.27
statistical Method
Regression, Logistic
ci Lower Limit
0.623
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.836
estimate Comment
The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
group Description
monotherapy as reference.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.8074
p Value Comment
P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.
param Type
Odds Ratio (OR)
param Value
1.07
statistical Method
Regression, Logistic

Complete source fields

analyses

ci Lower Limit
0.160
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
0.448
estimate Comment
The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY
p Value
<0.0001
p Value Comment
P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.
param Type
Odds Ratio (OR)
param Value
0.27
statistical Method
Regression, Logistic
ci Lower Limit
0.623
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.836
estimate Comment
The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
group Description
monotherapy as reference.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.8074
p Value Comment
P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.
param Type
Odds Ratio (OR)
param Value
1.07
statistical Method
Regression, Logistic

classes

categories
measurements
group Id
OG000
value
29.2
group Id
OG001
value
27.7
group Id
OG002
value
59.1

denoms

counts
group Id
OG000
value
137
group Id
OG001
value
137
group Id
OG002
value
137
units
Participants

description

groups

description
MEDI4736 (Durvalumab) + Tremelimumab
id
OG000
title
Combination Therapy
description
MEDI4736 (Durvalumab)
id
OG001
title
Monotherapy
description
Standard of Care Chemotherapy Treatment
id
OG002
title
Standard of Care

param Type

NUMBER

population Description

The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as: \<25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND \<25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.

reporting Status

POSTED

time Frame

Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).

title

Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice